CoChat

High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care

Ridker, Paul M · 2008 · Clinical Chemistry
Cited by 46

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Based on more than a decade of evidence, high-sensitivity C-reactive protein (hsCRP)1 is in clinical use as an inexpensive adjunct to global cardiovascular risk prediction, as a tool to determine risk of future diabetes and metabolic syndrome, and as a method for monitoring efficacy of statin therapy. In the last decade, more than 20 prospective cohort studies have indicated that hsCRP concentrations independently associate with future risk of myocardial infarction, stroke, metabolic syndrome, and type 2 diabetes, and most studies of adequate sample size have found that hsCRP adds prognostic information to global risk prediction scores. On this basis, guidelines for use of hsCRP in clinical practice have been issued by the Centers for Disease Control and Prevention (1), and novel algorithms for risk prediction that incorporate hsCRP, such as the Reynolds Risk Score (www.reynoldsriskscore.com), have been shown to improve risk classification, particularly for “intermediate risk” patients who account for more than 70% of all vascular events (2). Further, as statins lower hsCRP in an LDL cholesterol–independent manner and as best clinical outcomes occur among statin-treated patients who not only reduce LDL cholesterol below 700 mg/L (70 mg/dL) but also reduce hsCRP below 2 mg/L, the concept of “dual goals” has been introduced into cardiovascular clinical practice (3)(4). Because of its relationships with insulin resistance, leptin, and cytokine function (5), as well as its role in endothelial dysfunction and inhibition of fibrinolysis (6)(7), CRP has also been of pathophysiologic interest as an intellectual bridge linking low-grade systemic inflammation to both diabetogenesis and atherogenesis. Given the consistency and generalizability of these data, it is not surprising that clinical investigators might also seek evidence regarding CRP as a potential determinant of all-cause mortality. After all, coronary heart disease, cerebrovascular disease, and diabetes together account for >60% of adult deaths in the United States and Europe. In this issue of Clinical Chemistry, two reports address this research question from different perspectives, one evaluating CRP measurement among hospitalized patients and one evaluating hsCRP in a general outpatient community. In the first report, Marsik et al. (8) report that patients with CRP concentrations >5 mg/L at the time of hospital admission had a 50% to 330% increase in risk of death from any cause. This increase in risk was present in both short-term and long-term follow-up, rose in magnitude as concentrations of CRP increased >10 mg/L, and was associated with not only cardiovascular mortality but also mortality from cancer. Importantly, the mortality risk associated with increased CRP concentrations was independent of underlying disease status or reason for initial hospitalization. Characterizing CRP as a unique “triage marker for future death,” Marsik et al. argue that evaluation of inflammatory risk in the hospital setting should be routinely performed to identify very-high-risk patients in need of additional close monitoring. While provocative, this conclusion is consistent with data from prior investigations that have reported hsCRP to predict total mortality among patients hospitalized for acute ischemia, patients in general intensive care units, those undergoing bypass surgery, or in clinics limited to patients with diabetes, end-stage renal failure, chronic obstructive pulmonary disease, or cancer (9)(10)(11). The second report, from Koenig et al. (12), deals with the issue of hsCRP as a predictor of death in the Monitoring of trends and determinants in Cardiovascular Disease (MONICA)/KORA (Cooperative Health Research in the Region of Augsburg) Augsburg general population cohort in Southern Germany. In this prospective evaluation of 3620 initially healthy men followed over a 7.1-year period, 408 deaths occurred. After adjustment for age, smoking, hypertension, hyperlipidemia, diabetes, obesity, and socioeconomic markers, those with baseline hsCRP concentrations >3 mg/L had a 2-fold increase in risk of total mortality [hazard ratio (HR) 1.9, 95% CI 1.4–2.5]. Consistent with data from the hospitalized patients, risks in the MONICA/KORA Augsburg cohort associated with hsCRP were most prominent for vascular mortality (HR 2.2, 95% CI 1.4–3.3), but were also present for cancer mortality at a lower magnitude of effect (HR 1.7, 95% CI 1.0–2.7). Data from both of these studies confirm prior work in this field. As shown in Table 1 , 13 prospective cohort studies involving nearly 63 000 initially healthy individuals report that hsCRP concentrations are a potent predictor of short- and long-term risk of death (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). In most of these studies, increased hsCRP concentrations were associated with an approximate doubling in risk of both cardiovascular and all-cause mortality. Notably, higher risks are reported in studies of the elder

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2007.099465

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Ridker, P. M.
Venue
Clinical Chemistry
Published
2008-02-01
Volume
54
Issue
2
Pages
234-237
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2051237683
Cited by
46
References
6
FWCI
4.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.